Peptide lexicon
PT-141 (Bremelanotid)
Bremelanotide, a cyclic melanocortin peptide and metabolite of melanotan II with a free C-terminal acid; agonist mainly at MC4R and MC3R.
| Substance class | Peptide |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| CAS number | 189691-06-3 |
| Molecular formula | C₅₀H₆₈N₁₄O₁₀ |
| Molar mass | 1,025.2 g/mol |
| Synonyms | Bremelanotid |
| PubChem | CID 9941379 |
Structure
PT-141 differs from melanotan II only by the C-terminal carboxylic acid in place of the amide. This change shifts the receptor profile and reduces MC1R-mediated pigmentation.
Research focus
Animal models and clinical studies examine central MC4R activation. In the USA bremelanotide is approved as a medicine for a specific indication.
Status
There is no authorisation in the EU.
Literature
- Bremelanotide: First ApprovalDrugs, 2019 · PMID 31429064 · DOI 10.1007/s40265-019-01187-w
- Bremelanotide2006 · PMID 31369224
- PT-141 PalatinCurr Opin Investig Drugs, 2004 · PMID 15134289
- Bremelanotide for Treatment of Female Hypoactive Sexual DesireNeurol Int, 2022 · PMID 35076581 · DOI 10.3390/neurolint14010006
- Bremelanotide2012 · PMID 34436837
